On April 24, 2026, Duoc Cuu Long Pharmaceutical Joint Stock Company (Stock Code: DCL) successfully held its 2026 Annual General Meeting of Shareholders (AGM) via an online format.
During the meeting, shareholders reviewed and approved the 2025 operational reports of the Board of Directors, Board of Management, and Supervisory Board, while also discussing the Company’s operational plans for 2026. The AGM additionally approved proposals regarding the 2026 business plan, separate and consolidated audited financial statements for 2025, the selection of the auditing firm for 2026, and other matters under the authority of the General Meeting of Shareholders.
In 2025, Vietnam’s pharmaceutical industry continued to face increasingly intense competition from regional and international markets. In response to these challenges, Duoc Cuu Long Pharmaceutical Joint Stock Company (DCL) focused on evaluating and forecasting business conditions while implementing effective management strategies and solutions across all production and business activities. Supported by the strategic vision of F.I.T Group and DCL’s medium- and long-term development orientation, along with short-term initiatives such as digital transformation projects, investment in research and manufacturing upgrades, business cooperation, nationwide distribution network expansion, and export planning, DCL maintained stable operations and achieved 80% of the revenue target approved at the 2025 Annual General Meeting of Shareholders.
The 2026 AGM of DCL was conducted via an online meeting format.
In 2026, the Board of Directors will continue directing the Executive Board to implement key tasks and flexible business management solutions aligned with market conditions, with a focus on the Company’s core business segments.
In the pharmaceutical sector, DCL is concentrating resources on two major projects: the EU-GMP Pharmaceutical Manufacturing Plant Project in Tay Ninh – Phase 1, including the construction of an EU-GMP-standard oncology drug manufacturing facility and supporting infrastructure, as well as the upgrade project for the pharmaceutical manufacturing plant in Vinh Long to EU-GMP standards. In 2026, DCL also plans to cooperate with foreign partners on a “Functional Food Manufacturing and Trading” project. With 50 years of investment and development, pharmaceutical products manufactured by Duoc Cuu Long have earned the trust of customers and patients thanks to their quality and reasonable pricing. In addition to its existing manufacturing portfolio, DCL is diversifying its product range by expanding into pharmaceutical trading products, enabling the Company to better understand market demand, expand OTC and ETC distribution networks, and contribute significantly to overall business performance.
In the medical device sector, DCL completed Phase 1 of the Benovas Medical Device Manufacturing Plant, which officially commenced operations in March 2025. The plant’s key product lines include syringes, infusion sets, butterfly needles, and blood collection tubes. In 2026, with a strategy focused on both market expansion, including exports, and investment expansion for Phase 2, the medical device segment targets revenue of VND 188 billion, of which exports are expected to contribute VND 26 billion. At the same time, the factory will expand production and develop additional high-margin specialized products in areas such as emergency resuscitation and dialysis. Currently, DCL is investing heavily in the factory to improve quality standards and pursue FDA 510(k) and CE certifications.
In the empty capsule manufacturing segment, with stable production capacity and a tightly controlled quality management system, DCL currently supplies more than 80% of Vietnam’s empty capsule market, reaffirming its role as the leading supplier in this field. Through maintaining product quality, optimizing production processes, and improving operational efficiency, DCL continues to hold the number one market share position in Vietnam’s empty capsule industry. The empty capsule manufacturing plant is equipped with advanced technology imported from Canada, ensuring high technical standards, product consistency, and the ability to meet the stringent requirements of the pharmaceutical market. The modern production lines enable the factory to operate stably at high capacity, thereby meeting the rapidly increasing demand of customers as the empty capsule market continues to grow strongly.
With a spirit of consensus, responsibility, and innovation, DCL’s 2026 Annual General Meeting of Shareholders concluded successfully, reaffirming the strong connection between the Company’s leadership and shareholders on the journey toward sustainable development. The strategic orientations approved at the AGM not only serve as guiding principles for production and business activities in 2026 but also reflect Duoc Cuu Long’s strong aspiration to strengthen its position in Vietnam’s and the region’s pharmaceutical and healthcare industries. With a solid foundation, Duoc Cuu Long confidently enters a new phase of development—more efficient, more innovative, and more breakthrough-oriented.
